featured
Effect of PR Status on the Prognosis of Patients With Advanced ER-High HER2− Breast Cancer Receiving First-Line CDK4/6 Inhibitor Plus Endocrine Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
BMC Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy
BMC Cancer 2024 Jul 17;24(1)850, L Jia, J Peng, N Sun, H Chen, Z Liu, W Zhao, Q Zhang, L LiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.